Garonit Pharmaceutical, Inc.

Form 483 issued July 6, 2023 · Fairfield, New Jersey

Investigator
Janet A. Rajan
Observations
2
Pages
3
FEI number
3003961853

In short: On July 6, 2023, FDA issued a Form 483 with 2 observations to Garonit Pharmaceutical, Inc. in Fairfield, New Jersey (FEI 3003961853). The investigator was Janet A. Rajan. Most observations concern quality system; the most-cited regulation is 21 CFR 211.192 (production record review).

At a glance

2 of 2 observations on this 483 concern quality system.

Quality system2

Most cited: 21 CFR 211.192 (2×) · 211.100 (1×)

What FDA observed

Preview: the opening words of each observation

Dashed: section inferred by FDA Intel and checked against the regulation text

  1. 01

    (Repeat Observation) Failure to extend investigations to other batches that may have been associated with a…

  2. 02

    Failure to ensure all deviations are documented and investigated, and that…

The full 483

Plus the full detail behind each one, exactly as FDA wrote it.

Get the full 483

This inspection in context

Questions about this 483

What did FDA find at Garonit Pharmaceutical, Inc.?

FDA listed 2 observations on this Form 483, mostly about quality system. The most-cited regulation is 21 CFR 211.192 (production record review). The opening words of each observation are shown on this page.

Who inspected Garonit Pharmaceutical, Inc.?

Janet A. Rajan is named on this Form 483. Each investigator has a profile showing what they cite most.

When was Garonit Pharmaceutical, Inc. inspected by FDA?

This Form 483 is dated July 6, 2023.

How do I get the full Form 483 for Garonit Pharmaceutical, Inc.?

Download the original PDF from FDA Intel for $99, with no subscription. Your first Form 483 or letter is on us. You also get an invoice PDF with the order.

$99Get it free